| Description |
This is a single-arm, non-randomized and open-label clinical study to evaluate the safety of GC012F Injection in patients with refractory systemic lupus erythematosus (SLE) and determine the recommended phase II dose (RP2D). This study will be divided into screening, apheresis, baseline, lymphodepletion, infusion, and follow-up. Eligible subjects will receive the apheresis and then infusion after the production of CAR-T product. Subjects will be followed up for safety and efficacy after GC012F infusion. |
